Lymphedema is a major side-effect from breast cancer treatment. Discover MyLymphCare home monitoring and how we can decrease risk of lymphedema.
There is a gap between research and what we offer breast cancer survivors at risk of lymphedema today. Enabling early detection and compression treatment will have a significant positive impact on the lives of millions of breast cancer survivors.
Breast cancer survivors represent a large group of women that demand better solutions for a life after cancer.
Survival rates have increased and thus many more women live long lives after surviving breast cancer dealing with late-effects.
More than 20% of all breast cancer survivors are living with a diagnosis of lymphedema today.
Cacto Health is building MyLymphCare, the first at-home monitoring solution for breast cancer–related lymphedema. Today, too many breast cancer survivors face lifelong complications and stigma because lymphedema is detected late. Reshaping the use of traditional bioimpedance spectroscopy, we empower women to detect fluid changes early, track their recovery, and stay in control of their health.
By shifting monitoring from the hospital to the home, we are enabling women to stay active, independent, and reassured — while helping healthcare systems reduce cost and burden. Our mission is to put prevention at the center of women’s health.
Chief Executive Officer
PhD, researcher
Chief Technology Officer
M.Sc. Industrial Design
Regulatory Affairs/Quality Assurance Specialist
Medical Doctor
Commercial & Marketing
MBA & Founder of Chromaviso